Clinical and economic implications of topical cyclosporin A for the treatment of dry eye.
The purpose of this study was to investigate clinical, economic, and patient-reported outcomes related to topical cyclosporin A for the treatment of dry eye. The medical records of 181 patients with dry eye were reviewed (mean age, 67.6 yr; 72% women) for up to two years (average follow-up, 1.34 yr) before and after treatment with cyclosporin A 0.05% ophthalmic solution administered topically twice daily. Corneal staining, average discomfort scores, and patient satisfaction markedly improved, whereas the number of prescriptions for ancillary medications and dry eye-related visits to the ophthalmologist declined significantly during the treatment period. In a naturalistic clinical setting, topical cyclosporin A therapy improved the signs and symptoms of dry eye disease, resulting in high patient satisfaction, fewer patients with chronic dry eye visiting the ophthalmologist, and less ancillary drug use.
Cross
Warren D
WD
Bellaire Eye & Laser Center, Houston, USA.
Lay
Luis F
LF
Walt
John G
JG
Kozma
Chris M
CM
D000287:Administration, Topical; D000368:Aged; D016572:Cyclosporine / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000191:economics; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D014481:United States
D007166:Immunosuppressive Agents; D016572:Cyclosporine